Notice of Proposed Sale · 144
Recursion Pharmaceuticals, Inc.
RXRXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Recursion Pharmaceuticals, Inc.
- Issuer CIK
- 0001601830
- SEC file number
- 001-40323
- Phone
- 385-269-0203
- Person for whose account securities are to be sold
- Najat Khan
- Relationships to issuer
- Officer
- Street
- 41 S Rio Grande Street
- City
- Salt Lake City
- State / country code
- UT
- Postal code
- 84101
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 22,408 | 78,822.38 | 514,895,802 | 09/08/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 301 Tresser Blvd.
- City
- Stamford
- State / country code
- CT
- Postal code
- 06901
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/15/2026 | Equity Compensation | Recursion Pharmaceuticals | 18,422 | N | 08/15/2026 | Equity Compensation |
| Common | 08/15/2026 | Equity Compensation | Recursion Pharmaceuticals | 6,477 | N | 08/15/2026 | Equity Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 09/08/2026
- Signed
- Najat Khan
- Plan adoption dates
- 09/22/2025
Recent company filings
- SCHEDULE 13G - filed by STATE STREET CORP regarding RECURSION PHARMACEUTICALS, INC.Nov 10, 2026
- 4 filingNov 4, 2026
- 3 filingNov 4, 2026
- 10-Q filingNov 2, 2026
- Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureNov 2, 2026